Nivolumab for adjuvant treatment of invasive urothelial cancer at high risk of recurrence

  • Technology appraisal guidance
  • TA817
  • Published: 

Tools and resources

Tools and resources to help you put the guidance into practice.

Resource impact

Guidance into practice